The DOI matches its Crossref record; 330 of the 334 references it cites were found in a registry or an index.
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Open accessAbstract
Glioblastomas are the most common form of malignant primary brain tumor and an important cause of morbidity and mortality. In recent years there have been important advances in understanding the molecular pathogenesis and biology of these tumors, but this has not translated into significantly improved outcomes for patients. In this consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of isocitrate dehydrogenase wildtype (IDHwt) glioblastomas will be discussed. In addition, novel therapies such as targeted molecular therapies, agents targeting DNA damage response and metabolism, immunotherapies, and viral therapies will be reviewed, as well as the current challenges and future directions for research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For this patient population, there is currently no efficacious treatment option available [4].”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The current standard of care for GBM includes surgical resection and post-surgery radiotherapy with or without temozolomide (TMZ) chemotherapy [4, 5].”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Despite standard of care treatment, GBM recurrence is inevitable and there is no agreed salvage therapy post-recurrence [4, 5].”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Self-citationThe 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella‐Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,703
Ostrom, Q. T., Gittleman, H. R., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz‐Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 12,063
Self-citationStupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., TAPHOORN, M. J. B., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Bélanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,980
Self-citationComprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Self-citationGlioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,517
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Macrophage activation and polarization: nomenclature and experimental guidelines
Murray, P. J., Allen, J. E., Biswas, S. K., Fisher, E. A., Gilroy, D. W., Goerdt, S., Gordon, S., Hamilton, J. A., Ivashkiv, L. B., Lawrence, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.008 · Cited by 6,337
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Research works printed but not linked: 3
- World Health Organization., 2016, Histological Classification of Tumors of The Central Nervous System
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), 2019, Central Nervus System Cancers
- Chang, 2019, Neoplasms of the central nervous system., 1568
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Nithya Sree, P. R., Somarowthu, T., Jeyasankari, S., Kuncha, M., Andugulapati, S. B., & Bharate, S. B. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00105 · Cited by 1
Qian, Y., & Zhao, K. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07782-2 · Cited by 1
“Glioblastoma (GBM) is the most aggressive primary malignant tumor of the central nervous system, accounting for over 50% of all gliomas [1, 2].”
Akkara, Y., Hon, J. J., Rehman, S., de Groot, J., & Williams, M. (2026) · Neurosurgical Review · doi:10.1007/s10143-026-04328-4 · Cited by 1
“Despite optimised treatment consisting of maximal safe resection followed by radiation with adjuvant temozolomide, the median survival for GBM remains low [ 5, 6], with a 5-year with cancer cells and tumour microenvironments [ 12, 13 ] and drive tumour vascularisation [ 14, 15, 16].”
Gui, K., Li, Q., Xie, Z. Y., Zhan, T., Long, X., Yang, G., Luo, K., & Liu, H. (2026) · Progress in Biomedical Engineering · doi:10.1088/2516-1091/ae7860 · Cited by 1
Wang, L., Zhen, T., Liu, H., Sun, P., Wu, X., Chen, Y. C., & Sun, H. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119049 · Cited by 1
Celesti, F. (2026) · Clinical Immunology · doi:10.1016/j.clim.2026.110731 · Cited by 1
Alhalabi, O., Mironov, K., Nabiev, K., Ghraieb, A. N., Jordan, M., Joser, S., Bendszus, M., Krieg, S. M., Trong, P. D., Unterberg, A. W., et al. (2026) · Brain and Spine · doi:10.1016/j.bas.2026.106135 · Cited by 1
“Glioblastoma (GB) is an aggressive, therapy-resistant intrinsic brain tumor characterized by isocitrate dehydrogenase (IDH) wildtype status and poor prognosis (Stupp et al., 2005; Wen et al., 2020).”
Praeger, A., Davies, L., Munasinghe, T., Senanayake, H., Thomas, B., Bao, H., Wang, Y. Y., Moore, J. M., & Lai, L. (2026) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2026.112189 · Cited by 1
Qiu, R., Ojeda, A. V., Gonzalez, C., Abatay, V., Wu, J., Awabdeh, D., Starr, R., Carlesso, N., Shuck, S. C., Li, Y. R., et al. (2026) · Stem Cell Reports · doi:10.1016/j.stemcr.2026.103013 · Cited by 1
Chojak, R., Drewes, N. B., Słychan, K., & Lukas, R. V. (2026) · Journal of Neuro-Oncology · doi:10.1007/s11060-026-05734-w · Cited by 1
Müller, K. J., von Polenz, I., Reis, J., Wiegand, L., Mair, M. J., Aras, T., Isakaj, J., Schabhüttl, T., Barci, E., Forbrig, R., et al. (2026) · Neuro-Oncology · doi:10.1093/neuonc/noag182 · Cited by 1
Self-citationHammi, A., Shusharina, N., Gkika, E., & Nour, Y. (2026) · Physics and Imaging in Radiation Oncology · doi:10.1016/j.phro.2026.101070 · Cited by 1
“…as volumetric modulated arc therapy (VMAT) and Intensity-modulated radiation therapy (IMRT), have improved dose distribution conformality in brain treatments and reduced exposure to surrounding organs at risk, such as the brainstem, optic chiasm, optic nerves, hippocampi, and cochleae [16 – 18].”
Accelerating discovery: Transformative clinical trial models in neuro-oncology
Wisdom, A. J., & Rahman, R. M. (2026) · Neurotherapeutics · doi:10.1016/j.neurot.2026.e01080 · Cited by 1
“For example, glioblastoma (GBM), the most common primary malignant brain tumor, has not seen significant changes in standard-of-care therapy over the last two decades despite its devastating prognosis [3,4].”
Karimov, Z. M., Шамшиев, А. Т., & Mamytov, M. М. (2026) · Evrazijskij žurnal zdravoohraneniâ. · doi:10.54890/1694-8882-2026-1-126 · Cited by 1
PROGNOSIS IN IDH-MUTANT AND IDH-WILD TYPE GLIOBLASTOMA
KILIÇ, E., YELDİR, N., Özüm, Ü., Birsen, Y., Yılmaz, M., ÖZER, H., & Eğilmez, R. (2021) · Cumhuriyet Tıp Dergisi/Cumhuriyet Üniversitesi Tıp Fakültesi dergisi · doi:10.7197/cmj.945850 · Cited by 1
Molecular Biology in Treatment Decision Processes—Neuro-Oncology Edition
Krauze, A. V., & Camphausen, K. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413278 · Cited by 1
“The dose administered to high grade glioma is generally 60 Gy [38] and low-grade glioma 54 Gy [39] at 1.”
BackgroundGarcia, C. G., & Nespoli, J. (2022) · Brazilian Journal of Health and Biomedical Sciences · doi:10.12957/bjhbs.2022.68180 · Cited by 1
Ohno, M., Miyakita, Y., Takahashi, M., Yanagisawa, S., Tamura, Y., & Narita, Y. (2022) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyac114 · Cited by 1
Glioblastoma masquerading radiographically as herpes simplex encephalitis: A potential imaging trap
Aladamat, N., Gharaibeh, K., Al-Chalabi, M., & Sheikh, A. A. (2022) · Brain Disorders · doi:10.1016/j.dscb.2022.100063 · Cited by 1
Results of multicomponent treatment of patients with progression of primary brain glioma
Сарычева, М. М., Важенин, А. В., & Сергеевна, Д. А. (2023) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2023-22-1-110-118 · Cited by 1
Feasibility and tolerability of trofosfamide and etoposide in progressive glioblastoma
Schmidt, T., Agkatsev, S., Feldheim, J., Oster, C., Blau, T., Sure, U., Keyvani, K., Kleinschnitz, C., Stuschke, M., Herrmann, K., et al. (2023) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdad090 · Cited by 1
“(1) Age ≥ 18 years at the time of treatment initiation.”
Zhao, W., Chen, S., Shao, X., Du, H., Li, P., Wang, F., Chen, J., Feng, E., & Li, C. (2023) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_2248_21 · Cited by 1
Initial Treatment of IDH-Wildtype Glioblastoma in Adults Older Than 70 Years
Bao, J., Pan, Z., & Wei, S. (2023) · Cureus · doi:10.7759/cureus.47602 · Cited by 1
“The incidence of glioblastoma, the most common malignant primary brain tumour in adults, increases after 40 years of age and peaks in adults aged 75-84 years [1,2].”
BackgroundDrug therapy for brain glioblastoma
Rozanov, I. D., Lebedev, S. S., Греков, Д. Н., Yakusheva, T. A., & Балканов, А. С. (2023) · P A Herzen Journal of Oncology · doi:10.17116/onkolog20231205165 · Cited by 1
Zimmer, N., Trzeciak, E. R., Müller, A., Licht, P., Sprang, B., Leukel, P., Mailänder, V., Sommer, C., Ringel, F. A., Tuettenberg, J., et al. (2023) · Cancers · doi:10.3390/cancers15245711 · Cited by 1
“Glioblastoma (GB) is one of the most aggressive tumors, with an overall survival rate of approximately 15 months [1,2].”
BackgroundWang, L., Xu, Z., Zhang, W., Li, L., Liu, X., & Zhang, J. (2023) · iScience · doi:10.1016/j.isci.2023.108661 · Cited by 1
Zemskova, O. V., Glavatskyi, O., Gryazov, A. B., Stuley, V. A., & Starenkyі, V. P. (2023) · Український радіологічний та онкологічний журнал · doi:10.46879/ukroj.4.2023.362-377 · Cited by 1
The antitumor action of endocannabinoids in the tumor microenvironment of glioblastoma
Tang, Y., Wang, M., Yu, J.-P., Lv, G., Wang, Y., & Yu, B. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1395156 · Cited by 2
Shibli, Z., Kalhoro, A., Ahmed, K., & Hashim, A. S. M. (2023) · Pakistan Journal Of Neurological Surgery · doi:10.36552/pjns.v27i2.851 · Cited by 1
“The use of [18F] FDG is the established radiotracer for cancer imaging in PET, 4,5, and PET-CT scanning helps distinguish the active tumor area from radiation necrosis.”
MethodPrognostic Factors for Recurrent Glioma: A Population-Based Analysis
Fu, P., Shen, J., Song, K., Xu, M., Zhou, Z., & Xu, H. (2024) · Clinical Medicine Insights Oncology · doi:10.1177/11795549241252652 · Cited by 1
Aghedi, M., Larijani, A., Bagheri, A. B., Rafiemanesh, H., Saraee, E., Mardi, S., & Shirani, M. (2025) · Neurosurgical Review · doi:10.1007/s10143-025-03632-9 · Cited by 1
In the midst of crisis, a great opportunity
Strowd, R. E., III (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa143 · Cited by 1
Survival of elderly patients with glioblastoma after hypofractionated radiation therapy
Zemskova, O. V., Glavatskyi, O., Gryazov, A. B., Stuley, V. A., Starenkyі, V. P., & Zakrutko, A. O. (2023) · Український радіологічний та онкологічний журнал · doi:10.46879/ukroj.3.2023.255-270 · Cited by 1
ROAR trial: which treatment is effective after progression? – Authors' reply
Wen, P. Y., Burgess, P., Ilankumaran, P., & Subbiah, V. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00076-6 · Cited by 1
Self-citationTreatment of gliomas with temozolomide: Rather at sunrise or sunset?
Roth, P. (2022) · Neuro-Oncology Practice · doi:10.1093/nop/npac024 · Cited by 1
Self-citationPredictors of Citation Rates in High Impact Glioblastoma TrialsPreprint
Jamjoom, A. M., & Jamjoom, A. B. (2021) · Research Square · doi:10.21203/rs.3.rs-979223/v1 · Cited by 1
Peruzzi, P., Dominas, C., Fell, G. G., Blitz, S. E., Bernstock, J. D., Dawood, H. Y., Triggs, N. D., Ahn, S. W., Bhagavatula, S. K., Tatárová, Z., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1647435/v1 · Cited by 1
Self-citationZhang, Q., Li, X., Wang, R., Yu, Y., Mao, L., & Xu, P. (2022) · Research Square · doi:10.21203/rs.3.rs-2304486/v1 · Cited by 1
A brain neoplasm follow-up in a tertiary public hospital of northeast of Brazil: 2014-2016 data.Preprint
Maia, R. C. L., Ribeiro, H. L., Luciano3, M. C. D. S., Fiorenza, N. G., Ferraz, C. P. M., de Azevedo, O. G. R., Junior, E., Filho, S. D. C. A., & Sobrinho, O. P. D. C. (2023) · Research Square · doi:10.21203/rs.3.rs-2773800/v1 · Cited by 1
Pascuzzo, R., Doniselli, F. M., & Moscatelli, M. E. M. (2023) · European Radiology · doi:10.1007/s00330-023-10271-5 · Cited by 1
“To date, recommended therapy consists of surgery with maximal safe resection of the nodule with enhancement followed by radiotherapy and chemotherapy [1].”
MethodZhao, Y., Xu, Z., Zhang, Y., Liu, Y., Ye, M., Chen, R., Cao, Z., Zhou, H., & Zhou, Y. (2024) · Research Square · doi:10.21203/rs.3.rs-3913327/v1 · Cited by 1
Boshomane, T. M. G., Kgatle, M., Joseph, F., Padayachy, L. C., Bida, M., Ebenhan, T., Vorster, M., & Sathekge, M. M. (2024) · Preprints.org · doi:10.20944/preprints202406.1159.v1 · Cited by 1
Harbour, N., Curtin, L. A., Michaelides, L., Hubbard, M. E., Jackson, P., Rani, V., Kenchappa, R. S., Farias, V., Carrano, A., Owen, M. R., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.22.609156 · Cited by 1
“Glioblastoma (GBM) is the most common primary malignant brain cancer in adults (1,2).”
De, A., Forero, S. A., Pirani, A., Morales, J. E., Fuente, M. D. L., Sebastian, S., Huse, J. T., Ballester, L. Y., Weinberg, J. S., Lang, F. F., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.31.621280 · Cited by 1
Zhong, S., Pan, L., Yang, W., Jiang, Y., Zhang, D., Xie, Y., Wen, Y., Gao, M., Li, Z., Gao, Y., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5058452 · Cited by 1
Kala, E. Y., Aksu, F. S., Ercan, M. E., Ozbıyık, A., Cingöz, A., Yedier-Bayram, O., Aksu, A. C., Cavga, A. D., Yilmaz, E., Kok, İ., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.09.653010 · Cited by 2
Glioblastomas: clasificación, caracterización molecular y vías de señalización comúnmente alteradas
Alvarado, M. C. C., & Mora, D. T. (2020) · Revista Ciencia y Salud Integrando conocimientos · doi:10.34192/cienciaysalud.v4i4.184
Li, C., Huang, W., Chen, X., Wei, Y., Price, S. J., & Schönlieb, C. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2101.08757
Wen, P. Y., Weller, M., Chiocca, E. A., Lim, M. K., Tonn, J., Zadeh, G. M., Aldape, K., & van den Bent, M. J. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa305
Self-citationProgress on glioma surgery and multimodal treatments
Berger, M. S. (2021) · Glioma · doi:10.4103/glioma.glioma_9_21
Ahn, S., Kim, Y. I., Shin, J. Y., Park, J., Yoo, C., Lee, Y. S., Hong, Y.-K., Jeun, S., & Yang, S.-H. (2021) · Research Square · doi:10.21203/rs.3.rs-878192/v1
“There is no consensus regarding salvageable options for recurrent and TMZ-resistant adult glioma[7–10].”
Styś, S., Charmacińska, M., & Skrobała, A. (2021) · Letters in Oncology Science · doi:10.21641/los.2021.18.2.203
“Dla uzyskania dokładniejszych informacji o anatomii pacjenta w obszarze mózgowia niezbędnym jest wykonanie obrazowania za pomocą rezonansu magnetycznego [3,5].”
BackgroundInfluentialAdult primary brain tumours: presentation, diagnosis, treatment and complications
Tallant, J., & Soni, S. (2021) · Cancer Nursing Practice · doi:10.7748/cnp.2021.e1759
Biomarkers In Brain Tumors With Focus On Glioblastoma
Łysiak, M. (2022) · Linköping University medical dissertations · doi:10.3384/9789179291556
Nuclear medicine therapy of CNS tumors
Królicki, L., Kunikowska, J., Bruchertseifer, F., Koziara, H. M., Morgenstern, A., Królicki, B., Rosiak, E., Pawlak, D., & Merlo, A. U. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822960-6.00177-0
Ohno, M., Miyakita, Y., Takahashi, M., Yanagisawa, S., Tamura, Y., & Narita, Y. (2022) · Research Square · doi:10.21203/rs.3.rs-1492448/v1
Single-Cell Genetic Heterogeneity Linked to Immune Infiltration in GlioblastomaPreprint
Walentynowicz, K. A., Engelhardt, D., Yadav, S., Onubogu, U., Salatino, R., Vincentelli, C., McDonald, T. O., Franziska Michor, A., & Janiszewska, M. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3943617
Peruzzi, P., Dominas, C. A., Fell, G. G., Blitz, S. E., Bernstock, J. D., Dawood, H. Y., Triggs, D., Ahn, S. W., Bhagavatula, S. K., Tatárová, Z., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1647435/v2
Self-citationTumor–Host Interactions in Malignant Gliomas
Leiss, L. W., Mutlu, E., Rahman, M. A., Nilsen, M. H., & Enger, P. Ø. (2022) · Springer eBooks · doi:10.1007/978-3-030-98950-7_30
Molecular Profiling, Better Categorization of Gliomas Highlight Two Decades of Research
Samson, K. (2022) · Neurology Today · doi:10.1097/01.nt.0000855164.58448.be
Commentary: Predictors and Impact of Postoperative 30-Day Readmission in Glioblastoma
Dono, A., Rodriguez-Armendariz, A. G., & Esquenazi, Y. (2022) · Neurosurgery · doi:10.1227/neu.0000000000002156
Rozanov, I. D., Bunak, M. S., Glazkov, A. A., Stepanova, E. A., Lebedev, S. S., & Балканов, А. С. (2022) · Medical Radiology and radiation safety · doi:10.33266/1024-6177-2022-67-6-67-73
Gene Therapy For Neurological Disorders: Parkinson’s Disease And Glioblastoma
Zhao, P., & Goertz, T. (2022) · Journal of Student Research · doi:10.47611/jsrhs.v11i1.2425
Shard, C., Alexander, K. L., Gan, H. K., & Gomez, G. A. (2023) · F1000Research · doi:10.12688/f1000research.129089.1
Furtner, J., Weller, M., Weber, M., Gorlia, T., Nabors, B., Reardon, D. A., Tonn, J. C., Stupp, R., & Preusser, M. (2023) · doi:10.1158/1078-0432.c.6531057
Self-citationData from Imaging Tumor-Infiltrating Lymphocytes in Brain Tumors with [64Cu]Cu-NOTA-anti-CD8 PET
Nagle, V. L., Henry, K. E., Hertz, C. A. J., Graham, M. S., Campos, C., Parada, L. F., Pandit-Taskar, N. D., Schietinger, A., Mellinghoff, I. K., & Lewis, J. S. (2023) · doi:10.1158/1078-0432.c.6530541.v1
Self-citationWang, J., Weiß, T., Neidert, M. C., Toussaint, N. C., Naghavian, R., Moreno, C. S., Foege, M., Ojer, P. T., Medici, G., Jelčić, I., et al. (2023) · doi:10.1158/1078-0432.c.6532760.v1
Self-citationFurtner, J., Weller, M., Weber, M., Gorlia, T., Nabors, B., Reardon, D. A., Tonn, J. C., Stupp, R., & Preusser, M. (2023) · doi:10.1158/1078-0432.c.6531057.v1
Self-citationAragon‐Sanabria, V., Aditya, A., Zhang, L., Chen, F., Yoo, B., Cao, T., Madajewski, B., Lee, R., Turker, M. Z., Ma, K., et al. (2023) · doi:10.1158/1078-0432.c.6532640
Fouda, M. (2023) · Journal of Pediatric Neurology · doi:10.1055/s-0043-1768029
Wang, J., Zhang, H., Dang, X., Rui, W., Cheng, H., Wang, J., Zhang, Y., Qiu, T., Yao, Z., Liu, H., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1104610
Hadrup, S. R., Skadborg, S. K., Maarup, S. B., Draghi, A., Borch, A., Hendriksen, S., Mundt, F., Mann, M., Skjoeth-Rasmussen, J., Yde, C. W., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2976894/v1
A View of Molecular Targeted Therapies in Glioblastoma
Majumdar, E., & Chakraborty, A. (2023) · International Journal of Research Publication and Reviews · doi:10.55248/gengpi.4.723.49248
Tumor heterogeneity in glioblastoma
Verduin, M. (2023) · Research Publications (Maastricht University) · doi:10.26481/dis.20231113mv
Zhang, G., Tai, P., Fang, J., Wang, Z., Yu, R., Yin, Z., & Cao, K. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4638324
Lin, Q., Wei, Y., Xu, G., Xiao, X., Liang, J., Wang, L., Chen, X., Zhang, M., Zhang, A., Cheng, Y., et al. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4676977
Demencia rápidamente progresiva. A propósito de un caso
Peña-Lora, D., & Pena, B. P. (2023) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2023.101455
Moreau, N. N., Valable, S., Jaudet, C., Dessoude, L., Hérault, R., Modzelewski, R., Stefan, D., Thariat, J., Lechervy, A., & Corroyer‐Dulmont, A. (2024) · Research Square · doi:10.21203/rs.3.rs-4100227/v1
Peng, Y., Liu, H., Wu, Q., Wang, L., Yu, Y., Yin, F., Feng, C., Ren, X., Liu, T., Chen, L., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23597445
Peng, Y., Liu, H., Wu, Q., Wang, L., Yu, Y., Yin, F., Feng, C., Ren, X., Liu, T., Chen, L., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23597451
Peng, Y., Liu, H., Wu, Q., Wang, L., Yu, Y., Yin, F., Feng, C., Ren, X., Liu, T., Chen, L., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23597442
Li, R., Chen, H., Li, C., Qi, Y., Zhao, K., Wang, J., You, C., & Huang, H. (2023) · Figshare · doi:10.6084/m9.figshare.23625513
Peng, Y., Liu, H., Wu, Q., Wang, L., Yu, Y., Yin, F., Feng, C., Ren, X., Liu, T., Chen, L., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23597448
Peng, Y., Liu, H., Wu, Q., Wang, L., Yu, Y., Yin, F., Feng, C., Ren, X., Liu, T., Chen, L., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23597439
Huang, J., Tao, H., Chen, D., Yang, C., Nguyen, D., Liu, R., Liu, T., Chakraborty, A., Hou, A. Y., Petit, N. A., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4189094/v1
Terapias-alvo no tratamento do glioblastoma em adultos: Uma revisão de escopo
Ramos, R. N. A., Matsuda, T. Y. L., & Czepula, A. I. D. S. (2024) · Research Society and Development · doi:10.33448/rsd-v13i4.45474
Jiang, L., Li, Z., Jiang, T., Wang, X., & Weng, C. (2024) · Research Square · doi:10.21203/rs.3.rs-4270888/v1
Control of CDH1 and IDH1mut glioblastoma cell cycle by D-2- hydroxyglutaratePreprint
You, M.-Q., & Xu, W. (2024) · Research Square · doi:10.21203/rs.3.rs-4240423/v1
范, 琴. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1451644
Boshomane, T. M. G., Kgatle, M., Joseph, F., Padayachy, L. C., Bida, M., Vorster, M., & Sathekge, M. M. (2024) · Preprints.org · doi:10.20944/preprints202406.1120.v1
Sandoval-Bonilla, B. A., Vargas, M. F. D. L. C., Cosio, J. F., Gallardo-Ceja, D., Candelas-Rangel, J. A., Navarro-Domínguez, P., San‐Juan, D., Rodríguez-Florido, M. A., Trejo-Rosales, R. R., & Sánchez-Dueñas, J. J. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4870576
Neues zur Behandlung von Gliomen
Lazaridis, L., & Seliger, C. (2024) · Nervenheilkunde · doi:10.1055/a-2298-4551
Wilson, B. R., Peterson, C. M., Wei, H., Ying, M., Bartek, J. J., & Chen, C. C. (2024) · World Neurosurgery · doi:10.1016/j.wneu.2024.07.099
Сарычева, М. М., Важенин, А. В., & Сергеевна, Д. А. (2024) · P A Herzen Journal of Oncology · doi:10.17116/onkolog20241304135
Zhao, K., Hai, Z., Shang, R., Liang, H., Wang, C., Zhu, M., & Chen, W. (2024) · Research Square · doi:10.21203/rs.3.rs-4733991/v1
Shen, H., Mei, Q., Chai, X., Jiang, Y., Liu, A., & Liu, J.-C. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1429826
Glavatskyi, O., Gryazov, A. B., Stuley, V. A., LOESER, A., Rades, D., & Zemskova, O. V. (2024) · Experimental Oncology · doi:10.15407/exp-oncology.2024.02.129
“…that the variants sharing significant p values of the Kolmogorov — Smirnov test ( p 0.05) assessed by both interpolation methods can be considered more confident as to the rejection of the H0 hypothesis of no significant difference between CSS in the SRT and HRT groups (variants 10, 21, and 22).”
MethodInfluentialProgressi nel trattamento dei pazienti con glioblastoma
Pïcca, A., Santonocito, O. S., & Stefano, A. L. D. (2024) · EMC - Neurologia · doi:10.1016/s1634-7072(24)49605-0
Metadata
- Authors
- Wen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., Cloughesy, T. F., DeGroot, J. F., Galanis, E., Gilbert, M. R., Hegi, M. E., Horbinski, C., Huang, R. Y., Lassman, A. B., Le Rhun, E., Lim, M., Mehta, M. P., Mellinghoff, I. K., Minniti, G., Nathanson, D., Platten, M., Preusser, M., Roth, P., Sanson, M., Schiff, D., Short, S. C., Taphoorn, M. J. B., Tonn, J.-C., Tsang, J., Verhaak, R. G. W., von Deimling, A., Wick, W., Zadeh, G., Reardon, D. A., Aldape, K. D., & van den Bent, M. J.
- Affiliations
- Brigham and Women's Hospital (US)
- University of Zurich (CH)
- Case Western Reserve University School of Medicine and University Hospitals of Cleveland, Cleveland, Ohio, USA
- The Jackson Laboratory for Genomic Medicine (US)
- Yale University (US)
- University of California, San Francisco (US)
- University of California, Los Angeles (US)
- The University of Texas MD Anderson Cancer Center (US)
- Mayo Clinic (US)
- National Institutes of Health (US)
- Centre Hospitalier Universitaire Vaudois (CH)
- Northwestern University (US)
- NewYork–Presbyterian Hospital (US)
- University of Lille, Inserm, Neuro-oncology, General and Stereotaxic Neurosurgery service, University Hospital of Lille, Lille, France; Breast Cancer Department, Oscar Lambret Center, Lille, France and Department of Neurology & Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland
- Johns Hopkins University (US)
- Miami Cancer Institute, Miami, Florida, USA
- Memorial Sloan Kettering Cancer Center (US)
- University of Siena (IT)
- Heidelberg University (DE)
- Medical University of Vienna (AT)
- Centre National de la Recherche Scientifique (FR)
- University of Virginia (US)
- University of Leeds (GB)
- Leiden University Medical Center (NL)
- LMU Klinikum (DE)
- Neuropathology and Clinical Cooperation Unit Neuropathology, University Heidelberg and German Cancer Center, Heidelberg, Germany
- Princess Margaret Cancer Centre (CA)
- National Cancer Institute (US)
- Department of Neurology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
- Corresponding author
- Wen, Patrick Y
- Weller, Michael
- ORCID
- Wen, Patrick Y
- Weller, Michael
- Lee, Eudocia Quant
- Alexander, Brian M
- Barthel, Floris P
- Batchelor, Tracy T
- Bindra, Ranjit S
- Chang, Susan M
- Chiocca, E Antonio
- Cloughesy, Timothy F
- Galanis, Evanthia
- Gilbert, Mark R
- Hegi, Monika E
- Horbinski, Craig
- Huang, Raymond Y
- Lassman, Andrew B
- Lim, Michael
- Mehta, Minesh P
- Mellinghoff, Ingo K
- Minniti, Giuseppe
- Nathanson, David
- Platten, Michael
- Preusser, Matthias
- Roth, Patrick
- Sanson, Marc
- Schiff, David
- Short, Susan C
- Taphoorn, Martin J B
- Tonn, Joerg-Christian
- Tsang, Jonathan
- Verhaak, Roel G W
- Wick, Wolfgang
- Zadeh, Gelareh
- Reardon, David A
- Aldape, Kenneth D
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-04-24
- Volume
- 22
- Issue
- 8
- Pages
- 1073-1113
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- PMC
- PMC7594557
- OpenAlex
- W3020099303
- Cited by
- 1,168
- References
- 334
- Citations by year
- 2026: 166 · 2025: 215 · 2024: 242 · 2023: 204 · 2022: 194 · 2021: 118 · 2020: 28
- FWCI
- 71.12
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Neuro-Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- SERVAL (Université de Lausanne) (acceptedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion, cc-by-nc)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
- IRIS (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- JuSER (Forschungszentrum Jülich) (submittedVersion)
- LillOA (Université de Lille (University Of Lille)) (submittedVersion)
- The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Funders
- University of Leeds
- National Institutes of Health (UL1TR001863)
- National Cancer Institute (P01CA069246, P30CA008748, P50CA211015, P30CA016672, P01CA163205)
- National Institute of Neurological Disorders and Stroke (R35NS105109)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- glioblastoma, IDH-wildtype glioblastoma, adult brain tumors, molecular pathogenesis, targeted therapy, DNA damage response, metabolic therapy, immunotherapy, viral therapy, treatment management
- MeSH terms
- Brain Neoplasms, Glioblastoma, Humans, Isocitrate Dehydrogenase, Randomized Controlled Trials as Topic, Clinical Trials, Phase III as Topic, Chemoradiotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
